secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibitor Therapeutics, Inc. (INTI)
CIK:        0001042418
Form:       8-K
Filed at:   2022-01-18T23:59:59+00:00
Accession:  0001193125-22-011256
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibitor Therapeutics amends loan with Mayne Pharma: limit to $281K, maturity Dec 2022
--------------------------------------------------------------------------------

- Facility limit increased by $50,000 to $281,000; maturity extended to December 31, 2022.
- Additional $50,000 available for drawdown from Feb 1 to Mar 31, 2022, in minimum $25,000 increments.
- Original $231,000 fully drawn; proceeds used for working capital and deferred employee compensation.
- Loan amendment with majority stockholder Mayne Pharma; rest of Loan Agreement unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1042418/000119312522011256/0001193125-22-011256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1042418/000119312522011256/d284256d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-011256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer